Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2187)	1/22/2008 3:19:36 PM
From: Jibacoa	Respond to of 3722

HOLX volume is still below its ADV.The stock is down 1.29% as the volume is getting close to the 3M level. stockcharts.com It announced today that it has entered into an agreement to sell U.S. & worldwide rights to its Gestiva to KV Pharmaceutical upon approval of NDA by the FDA. Gestiva could be used in the prevention of preterm birth in women with a history of at least one spontaneous abortion.The drug was originally been develop by Adeza, which was acquired by Cytyc & was acquired on October 22 by HOLX from Cytyc. HOLX expects to be paid around $82M from its deal on Gestiva )$7.5M at closing of agreement & $82M on FDA approval & launch of the product.) Back on Dec 13 the FDA OBGYN Advisory Panel recommended that the pre-market application for its Adiana for female sterilization on a decision by a vote of 10 to 3.<g> The stock trades around 7.45xBV with a +CF around $2.60 The short ratio was up 137% in the last month & is now about 6x its ADV The stock needs to hold its support at the %58 to $60 level & close above its Jan4 H of $72,88 in order to make another all time H.<g> Bernard

To: Jibacoa who wrote (2187)	2/25/2008 11:37:21 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

IDEV has been up 11.43% & still is up 9.30% with volume of 753,248 just getting ahead of its ADV. bigcharts.marketwatch.com It announced earlier this month that it was advised by the United Kingdom's MMRC that after review of data from the PIII of PRO 2000 it recommended that the low-dose arm continue to be tested for safety and effectiveness & the high-dose arm be closed. MDP 301 is a multi-national, randomized, double-blind, placebo-controlled PIII trial designed to examine the safety and effectiveness of PRO 2000 in preventing HIV infection in women. Approximately 7,730 women have been enrolled in the trial so far & completion is expected in late 2009. As previously mentioned, the stock needs to close above $7.35 in order to get off from the DT coming from its Oct17 H at $8.22 & it has now resistance at the $6 level since my previous posting. <g> bigcharts.marketwatch.com Bernard